AnaptysBio Announces Change in Fiscal Year-End to June 30
On May 18, 2026, the Board of Directors of AnaptysBio, Inc. approved a change in the companyβs fiscal year-end from December 31 to June 30. As a result of this change, the company's next fiscal year is scheduled to begin on July 1, 2026. To account for the timing shift, AnaptysBio intends to file a transition report on Form 10-KT covering the six-month period from January 1, 2026, through June 30, 2026. Following this transition period, the company will commence filing quarterly reports based on the new fiscal cycle, starting with the quarter ending September 30, 2026. This administrative change aligns the company's financial reporting period with its new mid-year cycle. No clinical data, trial updates, or executive leadership changes were reported in this filing.